ArticleJournal of pediatric surgery2020
In utero treatment of myelomeningocele with placental mesenchymal stromal cells - Selection of an optimal cell line in preparation for clinical trials.
Article in Journal of pediatric surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preclinical stem cell therapy in fetuses with myelomeningocele: A systematic review and meta-analysis.Prenatal diagnosis · 2021Pooled it
- Fetoscopic Myelomeningocele (MMC) Repair: Evolution of the Technique and a Call for Standardization.Journal of clinical medicine · 2025Review
- Alternating 2D and 3D culture reduces cell size and extends the lifespan of placenta-derived mesenchymal stem cells.Frontiers in bioengineering and biotechnology · 2025Article
- Safety and efficacy of human umbilical cord-derived mesenchymal stromal cells in fetal ovine myelomeningocele repair.Stem cell research & therapy · 2024Article
- The Placenta as a Source of Human Material for Neuronal Repair.Biomedicines · 2024Review
- Biodistribution of allogenic umbilical cord-derived mesenchymal stromal cells after fetal repair of myelomeningocele in an ovine model.Stem cell research & therapy · 2022Article
- Early investigations into improving bowel and bladder function in fetal ovine myelomeningocele repair.Journal of pediatric surgery · 2022Article
- Impact of Gestational Age on Neuroprotective Function of Placenta-Derived Mesenchymal Stromal Cells.The Journal of surgical research · 2022Article
- Dural substitutes for spina bifida repair: past, present, and future.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Review
- Efficacy of clinical-grade human placental mesenchymal stromal cells in fetal ovine myelomeningocele repair.Journal of pediatric surgery · 2022Article
- Prenatal Neural Tube Anomalies: A Decade of Intrauterine Stem Cell Transplantation Using Advanced Tissue Engineering Methods.Stem cell reviews and reports · 2022Review
- Long-term safety evaluation of placental mesenchymal stromal cells for in utero repair of myelomeningocele in a novel ovine model.Journal of pediatric surgery · 2022Article
- Allografts for Skin Closure during In Utero Spina Bifida Repair in a Sheep Model.Journal of clinical medicine · 2021Article
- State of the art in translating experimental myelomeningocele research to the bedside.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Review
- Fetal myelomeningocele repair: a narrative review of the history, current controversies and future directions.Translational pediatrics · 2021Review
- Neural crest-like stem cells for tissue regeneration.Stem cells translational medicine · 2021Review
- Extracellular Matrix Mimicking Nanofibrous Scaffolds Modified With Mesenchymal Stem Cell-Derived Extracellular Vesicles for Improved Vascularization.Frontiers in bioengineering and biotechnology · 2020Article
- Surviving Lambs with Myelomeningocele Repaired in utero with Placental Mesenchymal Stromal Cells for 6 Months: A Pilot Study.Fetal diagnosis and therapy · 2020Article
- The CuRe Trial: Groundbreaking Innovation Raising Scientific and Ethical Questions.Discoveries (Craiova, Romania)Article
- Hydrogel and neural progenitor cell delivery supports organotypic fetal spinal cord development in anJournal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundWe determined whether in vitro potency assays inform which placental mesenchymal stromal cell (PMSC) lines produce high rates of ambulation following in utero treatment of myelomeningocele in an ovine model.
methodsPMSC lines were created following explant culture of three early-gestation human placentas. In vitro neuroprotection was assessed with a neuronal apoptosis model. In vivo, myelomeningocele defects were created in 28 fetuses and repaired with PMSCs at 3 × 10
resultsIn vitro, Line A and B had higher neuroprotective capability than no PMSCs (1.7 and 1.8 respectively vs 1, p = 0.02, ANOVA). In vivo, Line A and B had higher large neuron densities than no PMSCs (25.2 and 27.9 respectively vs 4.8, p = 0.03, ANOVA). Line C did not have higher neuroprotection or larger neuron density than no PMSCs. In vivo, Line A and B had ambulation rates of 83% and 71%, respectively, compared to 60% with Line C and 20% with no PMSCs.
conclusionThe in vitro neuroprotection assay will facilitate selection of optimal PMSC lines for clinical use. LEVEL OF EVIDENCE: n/a. TYPE OF STUDY: Basic science.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.